WINT (Windtree Therapeutics) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 1984. Start your Free Trial

What is Windtree Therapeutics 3-Year Revenue Growth Rate?

Windtree Therapeutics's Revenue per Share for the three months ended in Sep. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Competitive Comparison of Windtree Therapeutics's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, Windtree Therapeutics's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Windtree Therapeutics's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Windtree Therapeutics's 3-Year Revenue Growth Rate falls into.

Windtree Therapeutics 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Windtree Therapeutics (NAS:WINT) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Windtree Therapeutics 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Windtree Therapeutics's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Windtree Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Windtree Therapeutics Inc (NAS:WINT) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622

Website

https://www.windtreetx.com

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Executives

Craig Fraser	director, officer: Chief Executive Officer	AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Jamie Mcandrew	officer: VP, Controller, & CAO	WINDTREE THERAPEUTICS, INC., 2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Mark Strobeck	director	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
James Huang	director	9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
John P. Hamill	officer: SVP & CFO	4092 NEW HOPE ROAD, FURLONG PA 18925
Bioengine Capital Inc.	10 percent owner	7 F., NO. 3-2, PARK ST., NANGANG DIST., TAIPEI F5 11503
Center Laboratories, Inc.	10 percent owner	7 ., NO. 3-2, PARK ST. NANGANG DIST., TAIPEI F5 11503
Diane Carman	officer: SVP & General Counsel	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Eric Curtis	officer: SVP & COO	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Steven Simonson	officer: SVP, Chief Development Officer	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976
Evan Loh	director	75 KNEELAND STREET, BOSTON MA 02111
Leslie J. Williams	director	C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730
Robert A Scott	director
Joseph M Mahady	director	16640 CHESTERFIELD GROVE RD, SUITE 200, CHESTERFIELD MO 63005
Brian D Schreiber	director	2600 KELLY ROAD, SUITE 100, WARRINGTON PA 18976